BRPI0607302A2 - aminoácidos n-halogenados, aminoácidos n, n-dihalogenados e derivados, composição farmacêutica e estabilizada, método para controlar ou prevenir o crescimento de bactérias, micróbios, esporos, fungos ou vìrus ou a proliferação de infecções e da fonte de infecções e uso dos referidos compostos - Google Patents

aminoácidos n-halogenados, aminoácidos n, n-dihalogenados e derivados, composição farmacêutica e estabilizada, método para controlar ou prevenir o crescimento de bactérias, micróbios, esporos, fungos ou vìrus ou a proliferação de infecções e da fonte de infecções e uso dos referidos compostos

Info

Publication number
BRPI0607302A2
BRPI0607302A2 BRPI0607302-6A BRPI0607302A BRPI0607302A2 BR PI0607302 A2 BRPI0607302 A2 BR PI0607302A2 BR PI0607302 A BRPI0607302 A BR PI0607302A BR PI0607302 A2 BRPI0607302 A2 BR PI0607302A2
Authority
BR
Brazil
Prior art keywords
infections
amino acids
compounds
bacteria
growth
Prior art date
Application number
BRPI0607302-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Ramin Najafi
Mansour Bassiri
Lu Wang
Behzad Krosrovi
Original Assignee
Novabay Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novabay Pharmaceuticals Inc filed Critical Novabay Pharmaceuticals Inc
Publication of BRPI0607302A2 publication Critical patent/BRPI0607302A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0607302-6A 2005-01-25 2006-01-25 aminoácidos n-halogenados, aminoácidos n, n-dihalogenados e derivados, composição farmacêutica e estabilizada, método para controlar ou prevenir o crescimento de bactérias, micróbios, esporos, fungos ou vìrus ou a proliferação de infecções e da fonte de infecções e uso dos referidos compostos BRPI0607302A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64736605P 2005-01-25 2005-01-25
PCT/US2006/002875 WO2006081392A1 (en) 2005-01-25 2006-01-25 N-halogenated amino acids and n, n-dihalogenated amino acids in combination with hypohalous acids

Publications (1)

Publication Number Publication Date
BRPI0607302A2 true BRPI0607302A2 (pt) 2009-08-25

Family

ID=36441417

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607302-6A BRPI0607302A2 (pt) 2005-01-25 2006-01-25 aminoácidos n-halogenados, aminoácidos n, n-dihalogenados e derivados, composição farmacêutica e estabilizada, método para controlar ou prevenir o crescimento de bactérias, micróbios, esporos, fungos ou vìrus ou a proliferação de infecções e da fonte de infecções e uso dos referidos compostos

Country Status (14)

Country Link
US (1) US7846971B2 (enExample)
EP (1) EP1896001B1 (enExample)
JP (1) JP5329095B2 (enExample)
KR (1) KR20070098947A (enExample)
CN (1) CN101132785A (enExample)
AU (1) AU2006208046B2 (enExample)
BR (1) BRPI0607302A2 (enExample)
CA (1) CA2595889C (enExample)
ES (1) ES2421157T3 (enExample)
IL (1) IL184771A (enExample)
MX (1) MX2007008928A (enExample)
TW (1) TWI386201B (enExample)
WO (1) WO2006081392A1 (enExample)
ZA (1) ZA200706402B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1656095T3 (pl) * 2003-08-18 2014-04-30 Novabay Pharmaceuticals Inc N,n-dwuchlorowcowane kwasy aminowe i pochodne
US8747882B2 (en) 2005-04-21 2014-06-10 Astra Tech Ab Catheter assembly with bactericidal effect
CA2623576A1 (en) * 2005-09-21 2007-03-29 Novabay Pharmaceuticals, Inc. System and method for the prevention and treatment of bacterial and fungal infections including urinary tract infections (uti) using a hypohalous acid compositions
TWI432231B (zh) * 2005-10-06 2014-04-01 Novabay Pharmaceuticals Inc 使用ｎ-鹵化胺基酸於預防包括泌尿道感染（ｕｔｉ）之細菌性與真菌性感染的系統與方法
TW200843787A (en) * 2006-12-29 2008-11-16 Novabay Pharmaceuticals Inc N-halogenated amino compounds and derivatives; compositions and methods of using them
US20080287866A1 (en) * 2007-01-31 2008-11-20 Adam Heller Methods and compositions for the treatment of pain
UY31056A1 (es) * 2007-05-01 2008-10-31 Alcon Res Ltd Fromulaciones aminocido n-halogenado y metodos de limpieza y desinfeccion
UY31059A1 (es) * 2007-05-01 2008-10-31 Alcon Res Ltd Formulaciones de aminoacido n-halogenado
UY31057A1 (es) * 2007-05-01 2008-10-31 Alcon Res Ltd Formulaciones de aminoacido n-halogenado que contiene acido alifatico
UY31058A1 (es) * 2007-05-01 2008-10-31 Alcon Res Ltd Formulaciones de aminoacido n-halogenado con compuestos antiinflamatorios
UY31055A1 (es) * 2008-02-01 2008-10-31 Alcon Res Ltd Sales antimicrobianas de aminoacido n-halogenado
EP2265267B1 (en) 2008-04-10 2016-09-21 Waldemar Gottardi Compositions comprising n-halogenated or n, n-dihalogenated amine for treatment and prophylaxis of bronchopulmonary infections
WO2009127924A1 (en) * 2008-04-15 2009-10-22 Waldemar Gottardi Compositions and devices for antisepsis and anticoagulation
IL192262A (en) * 2008-06-17 2016-05-31 Z H T Eng Equipment And Tech Ltd A polymer that releases drugs into the animal body, a medicinal product containing it and a method for its preparation
WO2010017405A1 (en) * 2008-08-06 2010-02-11 Adam Heller Methods and compositions for the treatment of pain
CN102176818A (zh) * 2008-08-12 2011-09-07 诺华贝制药公司 抗微生物凝胶制剂
US8764638B2 (en) 2008-10-17 2014-07-01 Al Medical Devices, Inc. Endotracheal intubation device
EP2341886B1 (en) 2008-11-07 2015-08-26 NovaBay Pharmaceuticals, Inc. Antimicrobial n-chlorinated compositions
US8722715B2 (en) * 2008-11-07 2014-05-13 NovaBay Pharmaceuticals Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions
WO2010091280A1 (en) 2009-02-06 2010-08-12 Alcon Research, Ltd. N-halogenated amino acid formulations comprising phosphine or amine oxides
JP5587969B2 (ja) * 2009-03-18 2014-09-10 オラテック インダストリーズ リミティド ライアビリティ カンパニー 炎症及び疼痛の処置用の化合物
US20100272783A1 (en) * 2009-04-24 2010-10-28 Novabay Pharmaceuticals, Inc. Methods of Treating Infections of the Nail
US20110020474A1 (en) * 2009-07-27 2011-01-27 Novabay Pharmaceuticals, Inc. Methods of Treating Infections of the Nail or Skin Using Hypohalite
EP2531026A4 (en) * 2010-02-04 2013-09-25 Novabay Pharmaceuticals Inc ANTIMICROBIAL FORMULATIONS ON POLYSACCHARID BASE
US9888832B2 (en) 2010-09-24 2018-02-13 Blink Device LLC Endotracheal intubation device
TWI407907B (zh) * 2010-10-04 2013-09-11 Far Eastern New Century Corp An antibacterial agent with water solubility and biodegradability
CN103747770A (zh) 2011-06-15 2014-04-23 Rls全球股份公司 龋牙本质组织的检测和除去
SE536581C2 (sv) 2012-07-24 2014-03-11 Rls Global Ab Ett kit för behandling av sår eller liknande och ett preparat och metoder därav
CA3026576A1 (en) 2016-06-09 2017-12-14 Johnson Matthey Public Limited Company Electrolytic production of organic chloramine solutions
MX2020008026A (es) * 2018-01-30 2020-09-10 Buckman Laboratories Int Inc Combinaciones sinergicas de monocloramina y acido organico, y metodos de uso de las mismas para control microbiano.
CN113729039A (zh) * 2021-08-27 2021-12-03 上海罗克环控节能科技股份有限公司 一种绿色环保消毒液及其制造方法
US12251486B2 (en) 2021-09-09 2025-03-18 Toyota Motor North America, Inc. Vehicle sanitizing systems and methods for using the same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998945A (en) * 1972-06-12 1976-12-21 National Patent Development Corporation Dental treatment
US4015008A (en) * 1974-02-01 1977-03-29 National Patent Development Corporation N,N-dichloro substituted aminocarboxylic acids as microbiocides
US3950536A (en) * 1974-02-01 1976-04-13 Sol Joseph Barer N,N-Dichloro substituted aminocarboxylic acids as bactericides and fungicides
US4045578A (en) * 1974-06-14 1977-08-30 Interx Research Corporation N-chloro-amino acid derivatives exhibiting antibacterial activity
US3966796A (en) * 1974-06-14 1976-06-29 Interx Research Corporation N-chloro-amino acid derivatives activity
US4386103A (en) * 1981-01-30 1983-05-31 Merck & Co., Inc. Dichloroamino acid derivatives useful as potent germicidal and fungicidal agents
US5096700A (en) * 1990-09-28 1992-03-17 The Procter & Gamble Company Halogenated aminohexanoates and aminobutyrates antimicrobial agents
DE4041703C2 (de) 1990-12-24 1993-10-21 Waldemar Dr Gottardi Alkalimetallsalze des N-Chlortaurins in kristalliner Form, Verfahren zu deren Herstellung und deren Verwendung
JP3759757B2 (ja) * 1994-01-13 2006-03-29 相互薬工株式会社 殺菌剤
US5753701A (en) * 1996-10-25 1998-05-19 University Of Kentucky N-chloro-N-methyl glucamine and N-chloro-N-methyl glucamine esters as novel safe agents for water disinfection
DE19712565A1 (de) * 1997-03-25 1998-10-01 Thomas W Dr Stief Arzneimittel auf der Basis eines Singulett-Sauerstoff erzeugenden Agenzes
DE19816102C1 (de) * 1998-04-10 1999-09-16 Waldemar Gottardi Verfahren zum Inaktivieren von Viren in Proteinlösungen, Verwendung von N-Chlortaurin in dem Verfahren sowie nach dem Verfahren hergestellte Proteinlösungen
CA2320556A1 (en) 1999-09-29 2001-03-29 Queen's University At Kingston N,n-dichlorinated omega amino acids and uses thereof
EP1239853B1 (de) 2000-09-14 2006-11-08 Waldemar Gottardi Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
FR2819723B1 (fr) * 2001-01-23 2006-11-17 Arnaud Mainnemare Composition halogene, son procede de preparation et ses utilisations
AU2003279905A1 (en) * 2002-06-27 2004-01-19 Nicholas L. Geranio Integrated property database and search engine
PL1656095T3 (pl) * 2003-08-18 2014-04-30 Novabay Pharmaceuticals Inc N,n-dwuchlorowcowane kwasy aminowe i pochodne
US7129259B2 (en) * 2003-12-17 2006-10-31 Rib-X Pharmaceuticals, Inc. Halogenated biaryl heterocyclic compounds and methods of making and using the same
TW200843787A (en) 2006-12-29 2008-11-16 Novabay Pharmaceuticals Inc N-halogenated amino compounds and derivatives; compositions and methods of using them

Also Published As

Publication number Publication date
KR20070098947A (ko) 2007-10-05
IL184771A (en) 2013-04-30
US20060247209A1 (en) 2006-11-02
IL184771A0 (en) 2007-12-03
WO2006081392A1 (en) 2006-08-03
CN101132785A (zh) 2008-02-27
CA2595889A1 (en) 2006-08-03
AU2006208046A2 (en) 2006-08-03
EP1896001A1 (en) 2008-03-12
US7846971B2 (en) 2010-12-07
JP5329095B2 (ja) 2013-10-30
JP2008531479A (ja) 2008-08-14
TW200640445A (en) 2006-12-01
ZA200706402B (en) 2011-12-28
MX2007008928A (es) 2007-12-10
EP1896001B1 (en) 2013-06-19
ES2421157T3 (es) 2013-08-29
CA2595889C (en) 2013-11-19
TWI386201B (zh) 2013-02-21
AU2006208046B2 (en) 2011-03-24
AU2006208046A1 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
BRPI0607302A2 (pt) aminoácidos n-halogenados, aminoácidos n, n-dihalogenados e derivados, composição farmacêutica e estabilizada, método para controlar ou prevenir o crescimento de bactérias, micróbios, esporos, fungos ou vìrus ou a proliferação de infecções e da fonte de infecções e uso dos referidos compostos
BRPI0606107A2 (pt) compostos farmacêuticos, seus proocessos de preparação, usos dos mesmos na fabricação de medicamento e composição farmacêutica compreendendo os referidos compostos
BR112021012635A2 (pt) Compostos de 3-carbonilamino-5-ciclopentil-1 fi-pirazol tendo atividade inibitória sobre cdk2
MX2023007192A (es) Inhibidores de prmt5.
BR112023026976A2 (pt) Inibidores do inflamassoma nlrp3
TNSN06411A1 (en) Pyrimidine urea derivatives as kinase inhibitors
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
BRPI0816564B8 (pt) Composto, composição para proteger um animal de uma praga parasita invertebrada e método para proteger um animal de uma praga parasita invertebrada
BR112021023824A2 (pt) Inibidor de proteína quinase dependente de dna
BRPI0919873B8 (pt) compostos de pirazol[1,5-a]pirimidina substituídos como inibidores da trk quinase, seus processos de preparação e composições farmacêuticas
BR0315912A (pt) Compostos pirimìdicos com atividade antiproliferativa (ii)
BRPI0512676B8 (pt) derivados de indolil alquil amina substituídos como inibidores de histona desacetilase, composição farmacêutica que os compreende, seus processos de preparação e uso
MX2022007842A (es) Derivados biciclicos sustituidos de piperidina utiles como activadores de celulas t.
BRPI0510980A (pt) derivados de pirimidina para o tratamento do crescimento anormal de células
PE20090996A1 (es) Derivados de pirrolopirimidina como inhibidores de cinasa jak3
BR112012011072A2 (pt) inibidores de n1-pirazolospirocetona acetil-coa carboxilase
BR0116216A (pt) Inibidores de girase e seus usos
BR0212510A (pt) Inibidor de histona desacetilase, composto e composição
BR0016420A (pt) Aminotiazóis inibidores de cinases dependentes de ciclinas
BR0210874A (pt) Derivados de tiazol-benzamida e composições farmacêuticas para a inibição da proliferação celular e métodos para o seu uso
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
UA89123C2 (ru) Производные пиримидина для лечения абнормального роста клеток
BR0108613A (pt) Novo uso de derivados de fenilheteroalquiilamina
BRPI0810719A8 (pt) Inibidores da enzima diacilglicerol o-acetiltansferase tipo 1

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AOS DESPACHOS PUBLICADOS NA RPI 2161 DE 05/06/2012 E RPI 2194 DE 22/01/2013

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: NAO CONHECIDA PETICAO 020120083317 DE 05/09/2012, EM VIRTUDE DO DISPOSTO NO ARTIGO 219, INCISO II, DA LPI.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements